Back to Trials
NCT07058064NARecruiting

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

Mayo Clinic

Start Date

7/18/2025

Completion Date

6/29/2029

Summary

The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * ability to understand study procedures and being willing to comply with them for the entire study length * diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy Exclusion Criteria: * LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm * Unwilling or unable to give written informed consent * Participants who have opted out of the Minnesota Research Authorization

Interventions

PROCEDURE

Electrocardiogram

PROCEDURE

Echocardiogram

PROCEDURE

LVEF echocardiogram

OTHER

Apple Watch

PROCEDURE

Biospecimen collection

OTHER

Questionnaires

OTHER

Cardio-pulmonary exercise test

OTHER

6 minute walk test

OTHER

Grip strength test

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

LymphomaSarcoma

Locations

Mayo Clinic in Rochester

Rochester, Minnesota 55905

United States